Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526886 · ClinicalTrials.gov registry record · NA
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT04526886 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 52 participants.
The verdict
NCT04526886, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for reducing unplanned delays in patients receiving FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)-type chemotherapy, while maintaining acceptable chemotherapy dose-intensity.
Interventions
- OTHER Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2023-03-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04526886
The ClinicalTrials.gov registry entry for NCT04526886 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy is the first listed.
NCT04526886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04526886 about?
NCT04526886 is a clinical study titled "Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy". The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for reducing unplanned delays in patients receiving FOLFOX (5-fluorouracil, leu...
What is the current status of trial NCT04526886?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2020-10-15. Estimated completion is 2023-03-07.
What interventions are being tested in trial NCT04526886?
The interventions under investigation include: Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy (OTHER).
Who is sponsoring clinical trial NCT04526886?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.